Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies
This lecture was part of a CME accredited symposium: How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation held at ESC 2016 in Rome
Video navigation menu
Why LDL-C as target to reduce residual risk? 00:14
Why do we need further LDL-C lowering therapies? 02:32
The promise of PCSK9-inhibiting therapies 03:55
Ongoing phase III trials with PCSK9 inhibitors including ACS patients 09:45
The relation between PCSK9 inhibition and inflammation 10:10
Take home messages 13:48
Educational information
The educational objectives of this symposum were to:
- Discuss the potential of current and future strategies targeting inflammation in reducing residual risk in post ACS patients
- Outline current ongoing clinical development programs aimed at testing the inflammation hypothesis of cardiovascular disease
- Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients post ACS
- Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
- To review the clinical significance of additional lipid lowering pathways, such as ezetimibe, in the management of patients with ACS
- Understand the implications of new guidelines for lipid management
Disclosures
Prof. Erik Stroes, MD: - Chairman, Department of Vascular Medicine, Academic Medical Center, University of Amsterdam - Amsterdam, The Netherlands
Funding
This EBAC accredited symposium was funded by unrestricted educational grants received from Novartis, MSD, Amgen
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: